Literature DB >> 22452967

Provision and awareness for isoniazid preventive therapy among PLHIV in Addis Ababa, Ethiopia.

Amenu Wesen1, Getnet Mitike.   

Abstract

BACKGROUND: The risk of acquiring tuberculosis by People living with HIV (PLHIV) could significantly be reduced through provision of isoniazid preventive therapy (IPT). In Ethiopia, it is neither practiced well nor researched in depth. Our objective was to assess IPT provision and awareness among PLHIV in Addis Ababa City Administration.
METHODS: Between February 2008 and May 2008, a cross sectional facility-based survey was conducted by exit interview of 406 PLHIV from six health facilities. The findings were analyzed and described in this report.
RESULTS: The proportion of PLHIV ever had been provided with IPT were 74 of 231 TB free PLHIV (32.0%) and the proportion of having information about IPT among study participants was 29.8%. Females were about two times more informed about the provision of IPT in their health facilities than males [AOR (95%CI): 2.18 (1.31-3.61)].
CONCLUSIONS: We conclude that the practice of provision of IPT for PLHIV is high, but there is room for improvement. Provision of INH for TB free PLHIV has to be strengthened with better diagnostic facilities to certainly rule out active TB cases.

Entities:  

Year:  2012        PMID: 22452967      PMCID: PMC3353253          DOI: 10.1186/1472-698X-12-2

Source DB:  PubMed          Journal:  BMC Int Health Hum Rights        ISSN: 1472-698X


  9 in total

1.  Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.

Authors:  S Saenghirunvattana
Journal:  J Med Assoc Thai       Date:  1996-05

Review 2.  Drugs for preventing tuberculosis in HIV infected persons.

Authors:  D Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?

Authors:  K A Rowe; B Makhubele; J R Hargreaves; J D Porter; H P Hausler; P M Pronyk
Journal:  Int J Tuberc Lung Dis       Date:  2005-03       Impact factor: 2.373

4.  Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.

Authors:  D W Fitzgerald; M Desvarieux; P Severe; P Joseph; W D Johnson; J W Pape
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

5.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

Authors:  J W Pape; S S Jean; J L Ho; A Hafner; W D Johnson
Journal:  Lancet       Date:  1993-07-31       Impact factor: 79.321

6.  Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?

Authors:  Gavin J Churchyard; Katherine Fielding; Salome Charalambous; John H Day; Elizabeth L Corbett; Richard J Hayes; Richard E Chaisson; Kevin M De Cock; Badara Samb; Alison D Grant
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

7.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.

Authors:  A Mwinga; M Hosp; P Godfrey-Faussett; M Quigley; P Mwaba; B N Mugala; O Nyirenda; N Luo; J Pobee; A M Elliott; K P McAdam; J D Porter
Journal:  AIDS       Date:  1998-12-24       Impact factor: 4.177

8.  Knowledge of tuberculosis and associated health-seeking behaviour among rural Vietnamese adults with a cough for at least three weeks.

Authors:  Nguyen Phuong Hoa; Anna E K Thorson; Nguyen Hoang Long; Vinod K Diwan
Journal:  Scand J Public Health Suppl       Date:  2003       Impact factor: 3.021

9.  Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.

Authors:  Tom A Szakacs; Douglas Wilson; D William Cameron; Michael Clark; Paul Kocheleff; F James Muller; Anne E McCarthy
Journal:  BMC Infect Dis       Date:  2006-06-13       Impact factor: 3.090

  9 in total
  5 in total

1.  Assessment of national tuberculosis and HIV collaborative program implementation status in health care settings of Ethiopia.

Authors:  Wudinesh Belete; Minilik Demissie; Atsbeha Gebreegziabher; Desta Kassa; Gebremedine Gebre-Michael; Getnet Mesfin; Abebaw Kebede; Andargachew Kumsa; Lelissa Fekadu; Biruk Kebede; Fekadeselassie Mikru; Kassa Hailu; Addisalem Yilma; Eshetu Kebede; Ismael Hassen; Abera Bekele; Getachew Wondimagegne; Kumlachew Abate; Daniel Fiseha; Ezra Shimeles; Yibeltal Assefa
Journal:  Ethiop J Public Health Nutr       Date:  2017

2.  Utilization of isoniazid prophylaxis therapy and its associated factors among HIV positive clients taking antiretroviral therapy at Fre Semaetat primary hospital, Hawzien districts, Tigrai, Northern Ethiopia.

Authors:  Haftom Legese; Hagos Degefa; Aderajew Gebrewahd; Haftay Gebremedhin
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-06-17

3.  Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.

Authors:  Gebrehiwot Teklay; Tsigemariam Teklu; Befikadu Legesse; Kiros Tedla; Eveline Klinkenberg
Journal:  BMC Public Health       Date:  2016-08-19       Impact factor: 3.295

4.  Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa.

Authors:  Oladele Vincent Adeniyi; Nonkosi Selanto-Chairman; Eyitayo Omolara Owolabi; Anthony Idowu Ajayi; Dominique Kabengele Kayembe; Daniel Ter Goon; Avramovic Gordana; John Lambert
Journal:  BMC Public Health       Date:  2019-10-29       Impact factor: 3.295

5.  Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study.

Authors:  Ifeyinwa Chizoba Akamike; Ijeoma Nkem Okedo-Alex; Adaoha Pearl Agu; Chihurumnanya Alo; Lawrence Ulu Ogbonnaya
Journal:  Pan Afr Med J       Date:  2020-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.